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Borovicka, Jan, Werner Schwizer, Christine Met- 
traux, Christianna Kreiss, Brigitte Remy, Khaled Asal, 
Jan B. M. J. Jansen, Isabelle Douchet, Robert Verger, 
and Michael Fried. Regulation of gastric and pancreatic 
lipase secretion by CCK and cholinergic mechanisms in 
humans. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): 
G374-G380,1997.—Gastric lipase (HGL) contributes signifi­
cantly to fat digestion. However, little is known about its 
neurohormonal regulation in humans. We studied the role of 
CCK and cholinergic mechanisms in the postprandial regula­
tion of HGL and pancreatic lipase (HPL) secretion in six 
healthy subjects. Gastric emptying of a mixed meal and 
outputs of HGL, pepsin, acid, and HPL were determined with 
a double-indicator technique. Three experiments were per­
formed in random order: intravenous infusion of 1 ) placebo, 
2) low-dose atropine (5 /£g-kg~-h-1), and 3) the CCK-A 
receptor antagonist loxiglumide (22 /zmol • kg- •h-1). Atropine 
decreased postprandial outputs of HGL, pepsin, gastric acid, 
and HPL (P < 0.03) while slowing gastric emptying (P < 
0.05). Loxiglumide markedly increased the secretion of HGL, 
pepsin, and acid while distinctly reducing HPL outputs and 
accelerating gastric emptying (P < 0.03). Plasma CCK and 
gastrin levels increased during loxiglumide infusion (P < 
0.03). Atropine enhanced gastrin but not CCK release. Post­
prandial HGL, pepsin, and acid secretion are under positive 
cholinergic but negative CCK control, whereas HPL is stimu­
lated by cholinergic and CCK mechanisms. We conclude that 
CCK and cholinergic mechanisms have an important role in 
the coordination of HGL and HPL secretion to optimize 
digestion of dietary lipids in humans.
loxiglumide; atropine; pepsin; acid secretion; gastric empty­
ing
THE EXISTENCE OF gastric lipolysis has been known 
since the beginning of this century (41). Recently, the 
cellular origin of human gastric lipase (HGL) has been 
localized in the chief cells of fundic mucosa (28). HGL 
has been shown to be responsible for 25% of acyl chain 
hydrolysis during meal digestion (8). The colocation of 
HGL and pepsin and their correlated secretory re­
sponse to pentagastrin stimulation suggested common 
regulatory mechanisms of these two gastric enzymes 
(28, 39). Distinct receptors of the two important regula­
tory hormones, cholecystokinin (CCK) and gastrin, 
were previously identified in chief cells in the guinea 
pig stomach (10). Recently, different study groups re­
ported data on the regulation of gastric acid secretion 
by CCK in dogs and humans (22, 35). By use of specific 
CCK-A receptor antagonists (loxiglumide, MK-329),
these studies showed an inhibitory action of endog­
enous CCK on gastric acid secretion in contrast to the 
known stimulatory effect of CCK on pancreatic enzyme 
secretion in humans (2, 17). Although postprandial 
CCK-dependent regulatory mechanisms have been stud­
ied extensively for the pancreas, no data are available 
for gastric enzyme secretions in humans.
In this study we therefore applied the cholinergic 
antagonist atropine and the highly specific CCK-A 
receptor antagonist loxiglumide (36), which has been 
shown to inhibit markedly pancreatic enzyme secretion 
and gallbladder contraction in humans (2). Our aim 
was to define the physiological role of CCK and cholin­
ergic mechanisms in the regulation of postprandial 
gastric enzyme secretions in comparison to pancreatic 
enzyme secretions and to study the relationship be­
tween the secretion of HGL and pancreatic lipase 
(HPL) after a physiological meal in humans.
MATERIALS AND METHODS
Subjects
Studies were performed in six healthy subjects (5 men, 1 
woman) between 23 and 30 yr of age and 76 kg mean body 
weight (range 60-83 kg). All subjects were within 10% of 
their ideal body weight. No subject was taking any medica­
tion, nor did any subject have a history of gastrointestinal 
symptoms or prior surgery. The studies were approved by the 
local ethical committee of the University Hospital of Lau­
sanne, and all subjects gave written informed consent.
Experimental Procedure
Double-indicator technique. All studies were performed 
after an overnight fast. The subjects were intubated with a 
triple-lumen tube (5 mm OD), with the aspiration site (tip) at 
the ligament of Treitz. A marker perfusion site was located 20 
cm proximal to the tip, and the third canal of the tube ended 
in the antral portion of the stomach. A separate single-lumen 
nasogastric tube (3 mm OD) was placed in the most depen­
dent part of the stomach. The final position of the tubes was 
verified by fluoroscopy. With the subjects comfortably seated, 
an infusion of polyethylene glycol (PEG) 4000 (1.5 g PEG/100 
ml, 0.154 mol/1 saline) was begun through the proximal port 
of the duodenal tube at a rate of 1.5 ml/min. Duodenal 
contents were aspirated continuously during the experiments 
by means of a suction pump, which provided intermittent 
negative pressure. After an equilibration period, two premeal 
samples were collected from the duodenal tube in 15-min 
periods. Before meal administration the stomach was com­
pletely emptied by manual aspiration with a 50-ml syringe 
through the nasogastric and the proximal channel of the
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triple-lumen tube. A 500-ml mixed liquid test meal (Ensure, The specific activities of HGL and HPL measured at
Abott, Chicago, IL; diluted with 100 ml of distilled water) different pH values are shown in Pig. 1, demonstrating an
containing 16.8 g of protein, 13.4 g of fat, 53.4 g of carbohy- assay optimum for HPL at pH 8.0 and for HGL at pH 5.6. The
drate, and a total caloric value of 400 kcal (254 mosmol/1, pH activity of HPL was measured at pH 8.0 (specific activity =
7.0) was labeled with 99mTc-diethylenetriaminepentaacetic 1,785 U/mg purified HPL) using 1.5 ml of an emulsion
acid and infused intragastrically through the nasogastric containing 1.5 ml of triolein (Fluka, Buchs, Switzerland) in 35
tube over a standardized 7-min period. ml of buffer with 1 mM taurochenodeoxycholate, 9 mM
Sample collection. Gastric samples (10 ml) were collected taurocholate, 0.1 mM cholesterol, 1 mM phosphatidylcholine,
at the end of each 15-min period via the nasogastric tube by 15 mg of bovine serum albumin per milliliter (free fatty acid
means of a 20-ml syringe. Duodenal samples were continu- free), 2 mM tris(hydroxymethyl)aminomethane, 100 mM
ously siphoned on ice during 15-min periods after meal NaCl, and 0.2 mM CaCl2 (18). The interassay variation (n =
administration. Separate aliquots of gastric and duodenal 18) for HPL measurements was 6.4%, and the intra-assay
juices were treated as follows. Native gastric and duodenal variation (n ~ 5) was 1.1%.
samples were used for analysis of pH, acid content, PEG, and In duodenal samples, HGL and HPL activity could be
99mTc. For optimal storage conditions the pH of gastric and accurately discriminated. By lowering the pH of duodenal
duodenal samples was adjusted to 4-5 for analysis of HGL. To samples to 2 at 1 h before the HGL assay, HGL activity was
prevent proteolytic inactivation, turkey egg white inhibitor slightly increased [104 ± 1% (SE), n = 8], whereas HPL was
(10 mg/ml) was added to gastric and duodenal samples (23) completely inactivated and not measurable under standard
immediately after collection. Glycerol (50% vol/vol) was added assay conditions (Fig. 2). Furthermore, HGL activity was
to gastric samples for later pepsin measurements and to shown not to be influenced by the proteolytic action of pepsin
duodenal samples for HPL analysis. All duodenal samples when pure pepsin was added to gastric juice during a 1-h
were assayed within 1 mo for HGL and HPL activity. HGL incubation period at pH 2, confirming previous observations
showed no loss in activity after 1 and 2 mo when stored under (29). The HPL determination was highly specific, inasmuch
the above conditions. Blood was sampled through a separate as HGL and carboxyl ester lipase are not active under HPL
indwelling venous catheter at -30, -20, and -10 min and at standard assay conditions using the long-chain triacylglyc-
10, 20, 30, 45, 60, 90, 120, 150, and 180 min after meal erol triolein as substrate (17). Furthermore, HPL was mea-
administration. Blood samples were collected in 10-ml tubes sured at its pH optimum of 8.0, whereas HGL was determined
containing 16 mg of EDTA and 8,000 U of aprotinin and were at its optimal pH of 5.6.
immediately centrifuged (4°C, 3,000 rpm, 15 min). Immedi- HGL and HPL activities are expressed in international
ately after these different procedures, all samples were frozen units per milliliter (1 U = 1 ^mol of fatty acids released per
on dry ice and stored at -20°C until they were assayed. 
Experimental Protocol
Three experiments were performed in a randomized single­
minute). Furthermore, concentrations of the two lipases are 
also expressed in milligrams of protein of the respective 
lipase.
Enzyme-linked immunosorbent assay of HGL. In addition
blind order in the six subjects. Each experiment consisted of a to the measurement of enzyme activities, HGL was deter- 
60-min premeal period and a 180-min postmeal period, mined by a highly specific sandwich enzyme-linked immuno- 
Placebo (500 ml of 0.9% saline), atropine (5 Mg-kg^-h“1), or sorbent assay (ELISA) in duodenal juice, as previously de-
loxiglumide (Rotta Research Laboratorium, Monza, Italy; 66 
/^mol-kg"1-!!-1 for 10 min, then 22 ^mol-kg“1-!!“1 during the
scribed in detail (4). Briefly, the ELISA was performed using 
an anti-HGL polyclonal antibody as captor antibody and a
following 230 min) was administered by infusion pump biotinylated monoclonal antibody (MAb 35) as the detector
through a separate indwelling intravenous catheter. The antibody. Antibody binding was read by optical density at 490
infusion protocol of loxiglumide has been shown to result in nr^  using a Dynatech MR 5000 spectrophotometer. By use of 
steady-state plasma concentrations of loxiglumide in the ^ is sandwich ELISA procedure, the recovery of HGL added 
range of 150-250 j,tg/va\ (34) while completely inhibiting duodenal samples was 94 ± 4%.
pancreatic enzyme secretion and gallbladder emptying (14). 
Determinations
Gastric and duodenal samples were analyzed for PEG 
concentrations (26) and 99mTc activities. Duodenogastric PEG 
reflux was absent or negligible. Gastric acid concentrations 
were measured by titration of 1-ml samples to pH 7.0 with 
0.01 N NaOH using a pH-stat titration system (Metrohm, 
Herisau, Switzerland). Pepsin was determined in gastric 
juice by the method of Berstad (5) using human hemoglobin 
as substrate.
Lipase activity measurements. The activity of HGL was 
measured by the method of Borgström (7) using an automatic 
pH-stat titration system (Metrohm). The assay was per­
formed in a reaction vessel containing 1.5 ml of a mechani­
cally stirred emulsion prepared with 400 jâ of tributyrin (T 
8626, Sigma Chemical, St. Louis, MO) in 12 ml of buffer. The 
buffer contained 4 mM taurodeoxycholate, 2 mM tris(hydroxy~ 
methyl)aminomethane, 150 mM NaCl, and 0.2 mM CaCl2 at 
pH 7. Titration of HGL activity was performed at pH 5.6
Radioimmunoassays of CCK and gastrin. Plasma CCK 
concentrations were measured by a sensitive and specific 
radioimmunoassay (21). Antibody T204 binds to all CCK 
peptides containing the sulfated tyrosyl region of CCK. The 
antibody shows <2% cross-reactivity to sulfated forms of
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(specific activity — 318 U/mg purified HGL). The interassay Fig. i, Specific activity of purified human gastric lipase (HGL, v) 
variation (n = 36) for HGL measurements was 6.6%, and the and human pancreatic lipase (HPL, O) in relation to pH used at 
intra-assay variation (n = 5) was 2.3%. titration. Points are means of a2 measured values.
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prandial gastric secretions of the two enzymes, HGL 
and pepsin, and of gastric acid reached a peak at 75-90 
min after meal administration (Fig. 4). Loxiglumide 
markedly (P < 0.03) increased the secretion of HGL, 
pepsin, and gastric acid (Fig. 4, Table 1). Thus the 
infusion of loxiglumide caused a more than twofold 
increase in the cumulated postprandial HGL, pepsin, 
and acid secretion compared with placebo (Table 1).
Atropine almost completely inhibited gastric secre­
tion of HGL, pepsin, and acid (P  <  0.03; Fig. 4). The
cumulated outputs of postprandial HGL secretion were 
markedly lower during atropine than during placebo
infusion (18.4 ± 3.4 vs. 65.2 ± 6.2 mg for 120 min, P = 
0.028). In parallel, atropine distinctly decreased gastric 
outputs of pepsin (128.4 ± 28.3 vs. 397.6 ± 53.2 mg forFig. 2. Percentage of remaining activity of HGL (V) and HPL (O)measured titrimetrically (at pH 5.6 for HGL and at pH 8.0 for HPL) 1 _ ^
h after incubation at different pH values. Points are means of 3:2 120 min, P — 0.028) and acid (20.8 ± 3.5 VS. 49.0 ±7.5
measured values. mmol for 120 min, P =  0.028).
HGL secretion as determined in duodenal aspirates
,. , , J . TJ , , showed a late maximal rise after 90 and 120 min and
gastrm and no binding to nonsulfated gastrins It does not markedly augmented by loxiglumide compared
cross-react with structurally unrelated gastrointestinal pep- -, , /L. E A, . J ® i j . i -  t.--l
tides. Synthetic CCK octapeptide (CCK-8) coupled to 125I- with placebo (Fig. 3). Atropine almost comple  ^e y mhib-
hydroxyphenylpropionic acid succinimide ester (Bolton- HGL secretion. Cumulated HGL outputs as mea- 
Hunter reagent) was used as a standard. The detection limit sured by lipase activity assay and ELISA were mark­
of the assay was 0.5 pmoL/1 plasma, and the extraction edly increased by loxiglumide and decreased by atropine
recovery was 90 ± 2% when sulfated CCK-8 was added to (Table 2). Thus there was an excellent correlation of 
hormone-free plasma. The intra- and interassay variations HGL outputs measured by the two different methods
were 8% and 11%, respectively, at 2.6 pmol/1.
Plasma gastrin levels were measured by a sensitive and
O 0.7453, P <  0.001).
specific radioimmunoassay, as previously described in detail Duodenal HPL Outputs
(6). The intra-assay variation was 7 ± 3% (mean 
20). All samples were analyzed in the same run.
Calculations and Statistical Analysis
SD, n
Loxiglumide markedly suppressed basal HPL out­
puts (1.7 ± 0.3 mg/15 min, P  < 0.05). Atropine also
Gastric meal emptying and gastric acid, HGL, and pepsin 
outputs were calculated according to previously published 
methods (24). Cumulated gastric acid, HGL, and pepsin 
outputs were calculated at the time when >90% of gastric 
contents had left the stomach. Secretory outputs of HGL and 
HPL passing the duodenal sampling site were calculated 
from the product of enzyme concentrations and flow rates. 
99mTc recovery (marker given with the test meals corrected for 
the amount of 99mTc aspirated from the stomach) was 83 ± 5% 
(SE). Flow rates passing the duodenal sampling site were 
calculated on the basis of known infusion rates and PEG 4000 
concentrations at the infusion and sampling ports. The 
emptying curves were fitted to a power exponential model, as 
described previously (11). The area under the curve (ATJC) 
and half emptying time were calculated for each individual 
curve.
Values are means ± SE. Cumulated gastric acid, HGL, 
pepsin, and HPL outputs were calculated. Increments of CCK 
and gastrin concentrations were computed by subtracting the 
basal from the postprandial values, and integrated incre­
ments (AUC) were then calculated. Responses were compared 
by the Wilcoxon signed rank test. Differences were considered 
significant at P < 0.05.
RESULTS
Gastric Enzyme and Acid Secretion
There was no significant difference among basal 
duodenal outputs of HGL during placebo (0.9 ±
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atropine (0.5 ± 0.2 mg/15 min) infusion (Fig. 3). Post- subjects.
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Table 2. Effects of loxiglumide and atropine on 
cumulated postprandial duodenal outputs (180 min)
of HGL and HPL
HGL HGL HPL
Experiment Activity, mg ELISA, mg Activity, mg
Placebo 22.0 ±5.8 24.7 ±9.1 245 ± 22
Loxiglumide 40.9 ±7.1* 83.0 ±31.4* 119 ± 17*
Atropine 5.3± 1.1* 5.4 ± 1.4* 97.5 ±26.2*
Values are means ± SE. HPL, human pancreatic lipase; ELISA, 
enzyme-linked immunosorbent assay. *P < 0.03 vs. placebo.
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cumulated outputs of HPL were decreased distinctly by 
atropine and loxiglumide (Table 2).
Gastric Emptying
Loxiglumide distinctly accelerated gastric emptying
of the mixed liquid meal (P < 0.03; Fig. 5). AUC
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(3,703 ± 184 vs. 5,720 ± 457 pM-min, P < 0.03) and 
half emptying time (29.7 ± 1.5 vs. 51.1 ± 4.7 min, P <  
0.03) were considerably decreased by loxiglumide com­
pared with placebo. Atropine slowed gastric emptying
slightly (AUC = 6,911.8 ± 624.2 vs. 5,720.3 ± 456.5 
pM • min, P < 0.05) without a significant delay of the 
half emptying time (63.4 ± 5.7 vs. 51.1 ± 4.7 min, P = 
0.075).
Plasma Gastrin and CCK
Basal plasma gastrin concentrations remained un­
changed during the infusion of loxiglumide (7.3
T
0 30 60
T
90 120
Time (min)
1.8
and 8.2 ± 2.1 pM without and with loxiglumide, 
respectively) and atropine (13.8 ± 4.9 pM, P = NS). 
Maximal plasma levels were measured 10-20 min after 
meal administration during placebo (26.8 ± 6.4 pM), 
loxiglumide (46.2 ± 10.3 pM), and atropine (37.7 ± 11.6 
pM) infusions (Fig. 6). Postprandially, integrated gas­
trin values (AUC) were markedly increased by loxiglu­
mide compared with placebo (3,234 ± 570 vs. 1,982 ±
Fig. 4. Gastric outputs of HGL, pepsin, and acid after an intragastric 419 pM'min, P < 0.03) and were significantly aug-
mixed meal during infusion of placebo (O) atropine (V, 5 //.g - kg“1 -h' x), mented by atropine (2,743 ± 573 pM-min,P < 0.05).
and loxiglumide ( • ,  22 ywmol'kg 1 • hr1 ). Values are means ± SE of 6 
subj ects.
Basal plasma CCK concentrations were not altered 
by the infusion of loxiglumide (2.3 ± 0.4 pM) and
atropine (2.2 ± 0.3 pM) compared with placebo (2.7 :I-
reduced basal HPL outputs (2.0 ± 0.9 mg/15 min, P <  
0.03) compared with placebo (8.5 ± 2.5 mg/15 min; Fig. 
SB). The postprandial HPL secretion is shown in Fig. 3. 
HPL secretion reached a maximum 30 min after meal 
administration during infusion of placebo; loxiglumide 
and atropine suppressed this early postprandial re­
sponse to a similar degree by >50%. Accordingly, the
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Table 1. Effects of loxiglumide on cumulative 
postprandial gastric outputs (75 min) of HGL, 
pepsin, and HCl secretion
COE
xeQ.
O
r-
s
40
20
Experiment HGL, mg Pepsin , mg HCl, mmol
Placebo 31.5 ±8.7 174 ± 43 21.3 ±4.2
Loxiglumide 64.7 ±22.4* 309 ± 73* 51.6 ±9.6*
0
0 30 60 90 120 150 180
Time (min)
Values are means ± SE. HGL, human gastric lipase. *P <  0.03 vs.
placebo.
Fig. 5. Gastric emptying of a il9mTc-labeled liquid mixed meal during 
infusion of placebo (O) atropine (v, 5 jug• kg~1 • h"1 ), and loxiglumide 
{ • , 22 /i.mol • kg 1 • h 1 ). Values are means ± SE of6subjects.
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stimulation of postprandial gastric secretion of the two 
gastric enzymes, HGL and pepsin, consistent with a 
negative-feedback regulation by CCK. Furthermore, 
our experiments outline the presence of a parallel 
postprandial secretion of HGL, pepsin, and gastric acid 
commonly regulated by CCK and cholinergic mecha­
nisms. These findings are in line with previous studies 
showing a parallel secretion of HGL and pepsin after 
exogenous injection of pentagastrin and a common 
regulation of pepsin and gastric acid in humans (20, 
39). In analogy to the parallel secretion of digestive 
enzymes by the pancreas, the postprandial gastric 
secretion of HGL and pepsin may be explained by their 
colocation in human gastric chief cells, as recently 
shown by immunocytochemical studies (28). The inhibi­
tion of postprandial gastric acid outputs by CCK as 
shown in our study confirms previous results obtained 
in humans by gastric pH-metry and by measurement of 
stimulated acid output (22,35).
The mechanisms by which CCK exerts its regulatory 
action on postprandial gastric enzyme and acid secre-
Fig.6. Plasma cholecystokinin (CCK) and gastrin before and after an tion are poorly understood. In our study, parietal and 
intragastric mixed meal during infusion of placebo (O) atropine (V, 5 chief cell secretion were stimulated by loxiglumide,
^  if ,loxi,glumide (•> 22 -umo1 'kg 1-h Values are although these two gastric mucosal cells differ consider-
J ably in their cell receptors for CCK and gastrin. CCK-A
receptors of the pancreatic type, absent in parietal 
0.4 pM). Maximal increments were reached 10 min cells, were identified in the rabbit chief cell by cDNA 
after meal instillation during placebo (5.5 ± 0.9 pM), cloning (19). Whereas the presence of CCK-A receptors 
loxiglumide (11.0 ± 1.1 pM), and atropine (5.7 ± 0. 7 has been demonstrated in a model of gastric chief cells, 
pM) infusion followed by a gradual decline (Fig. 6). their functional relevance regarding HGL and pepsin 
Postprandially, loxiglumide markedly increased inte- secretion remains unclear. CCK is a full gastrin agonist
x.
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grated CCK values (AUC) compared with placebo (765
98 vs. 173 ±
had no effect on CCK release (270 ± 5 5  pM • min).
DISCUSSION
that acts through a CCK-B-type gastrin receptor on
117jpM-min, P  <0.03), whereas atropine parietal cells, exerting only a weak agonist activity in
vivo and potently inhibiting pentagastrin-stimulated 
gastric acid secretion (37). In contrast to the inhibitory 
action on gastric enzyme and acid secretion in vivo, 
HGL has recently been identified to be one of the key CCK-8 potently stimulates HGL secretion in rabbit and 
enzymes of fat digestion in humans (1,8). However, the human gastric glands (10, 13). Thus the different 
regulation of its secretion has remained poorly under- CCK-type receptors on gastric chief (CCK-A) and pari- 
stood. We have demonstrated that gastric and pancre- etal cells (CCK-B) do not indicate a common regulatory 
atic lipolysis are regulated by CCK and cholinergic mechanism through CCK-A receptors located in the 
mechanisms in a different and specific way. Thus the gastric gland. However, potentially more sensitive inter- 
infusion of the specific CCK-A receptor antagonist mediary neuroceptors for CCK, located in capsaicin- 
loxiglumide stimulated postprandial secretion of HGL, sensitive vagal afferent fibers in the gastric wall, may 
pepsin, and acid while inhibiting pancreatic secretion mediate the inhibitory effect of CCK on gastric secre- 
of HPL. Low-dose atropine inhibited gastric and pancre- tion and emptying and may explain the discrepancy 
atic enzyme secretions. Furthermore, we found a paral- between in vitro stimulation and in vivo inhibition of 
lei secretion of the two gastric enzymes, HGL and gastric secretion (32). Other mechanisms, such as the 
pepsin, both being inhibited by CCK and stimulated by paracrine secretion of somatostatin, might be candi- 
the cholinergic system. In addition, we confirmed in dates for this regulation, inasmuch as somatostatin 
this study the inhibitory effect of postprandially re- inhibits secretion of parietal and gastric chief cells (25).
leased CCK and atropine on gastric meal emptying. In vitro models show that somatostatin interacts with a
Loxiglumide markedly inhibited postprandial HPL specific somatostatin subtype receptor (SSTR-2) on
secretion while distinctly increasing HGL and pepsin gastrin and histamine cells in humans (42). In vivo
secretion, indicating complementarity in the regulation experiments in dogs confirm an inhibitory effect of
of the two main lipolytic enzymes, HGL and HPL. In somatostatin analogs on postprandial gastric acid secre-
contrast, in a previous study with exogenously adminis- tion through the same receptor subtypes (15).
tered intravenous CCK, no regulatory effect of CCK on Our study design enabled us to measure postpran-
HGL secretion was found (30). Thus, by applying the dial HGL secretion and to investigate simultaneously 
specific CCK-A antagonist loxiglumide, we could demon- the duodenal lipolytic activity of HGL and HPL. More- 
strate, to our knowledge for the first time, a marked over, HGL outputs were measured by a titrimetrical
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and an enzyme-linked assay to quantify the activity tion. The inverse relationship of acid inhibition and
and the concentration of HGL. The two assay methods gastrin stimulation during atropine infusion was previ-
showed an excellent correlation, with differences only ously reported in humans and may be explained by a
at high secretory rates of HGL. This is probably due to a suppressed somatostatin activity, resulting in a second-
partial inactivation of HGL by proteases, resulting in ary increase of gastrin release (12,33). Studies with the
lower HGL activities than quantified by ELISA. Corre- selective gastrin receptor antagonist YM-022 in rats
spondingly, higher amounts of HGL were measured showing no inhibition of bethanechol- and histamine-
titrimetrically in gastric contents than in the duode- stimulated acid secretion question the importance of
num with its high concentrations of proteases. Confirm- gastrin in the regulation of gastric acid secretion (31).
ing previous observations (8), we found that the maxi- Further studies with CCK-B/gastrin receptor antago-
mal HGL output was different 45 min after meal nists in humans are needed to clarify the role of
ingestion at the gastric and the duodenal site, which endogenous gastrin in gastric acid secretion and gastric
can be explained by a late and incomplete emptying of fat digestion.
the enzyme-rich gastric mucus. CCK release was unaffected by atropine and consider-
The administration of low-dose atropine resulted in ably increased during loxiglumide infusion. The phe-
decreased outputs of HPL in the duodenum and of HGL nomenon of enhanced CCK release during CCK-A
at the duodenal and gastric sampling sites. Atropine receptor blockade has been previously reported (14)
reduced HPL activity by -50% , similar to previously and is explained by the inhibition of gallbladder empty-
reported experiments with Lundh meals (16). In an- ing and, jn consequence, the interruption of a bile
other study an almost complete inhibition of HPL was 
obtained with the same dose of atropine (5 p,g-kg-1 • hr1)
acid-mediated feedback mechanism on CCK release. 
This hypothesis was recently confirmed in a study with
after intraduodenal perfusion of the test meal (3). The different bile salt binders in humans, demonstrating 
cholinergic regulation of gastric secretion of acid and that bile salt sequestration, but not protease inactiva- 
pepsins was previously studied in humans and dogs tion, enhances plasma CCK levels stimulated by bombe-
(12). This study demonstrates that HPL and HGL are 
regulated by muscarinic pathways, the latter in paral-
sin in humans (40).
In conclusion, the postprandial gastric secretion of
lei to gastric pepsin and acid secretion, confirming lipase, pepsin, and acid occurs in parallel and is stimu- 
previous observations in vagotomized patients (39) and iated by cholinergic mechanisms while being inhibited
studies on gastric acid and pepsin secretion (12, 38). by CCK. HPL secretion is stimulated by cholinergic
Thus the present study confirms and extends these mechanisms and CCK. Thus the regulation of postpran-
previous results demonstrating cholinergic inhibition 
of gastric acid, pepsin, HGL, and HPL secretion (39).
dial fat digestion by CCK consists of a positive pancre­
atic stimulation and a negative-feedback mechanism
We and other groups have shown previously that 0n HGL secretion. The main mechanisms postulated by 
CCK potently inhibits gastric emptying in animals and which CCK coordinates gastric and pancreatic fat 
humans (9, 14). In the present^study, CCK-A receptor digestion include vagal pathways and the stimulation
of paracrine somatostatin secretion.
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lation of gastric emptying implies adrenergic ganglia 
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